Aberrant Akt activation is prevalent across cancer lineages, is responsible for cancer cell survival, and is closely correlated with adverse clinical outcomes in patients with cancer, such as glioma, ovarian cancer, lung cancer, and pancreatic cancer. This evidence concerns the gene AKT1 and cancer.